# PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

> **NCT00567840** · PHASE2 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 69 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** PA-824

## Key facts

- **NCT ID:** NCT00567840
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00567840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00567840, "PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00567840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*